7-[5-(2-ethyl-3-methyl-3,4-dihydro-1H-isoquinolin-7-yl)-1H-indol-3-yl]-2,2-dimethyl-1-propan-2-yl-3H-imidazo[1,2-a]pyrimidin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 7-[5-(2-ethyl-3-methyl-3,4-dihydro-1H-isoquinolin-7-yl)-1H-indol-3-yl]-2,2-dimethyl-1-propan-2-yl-3H-imidazo[1,2-a]pyrimidin-5-one
• 化学式: C₃₁H₃₇N₅O
• 分子量: 495.7
• InChiKey: WUYBVVDPJIBWQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] INDOLYLDIHYDROIMIDAZOPYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS D'INDOLYLDIHYDROIMIDAZOPYRIMIDINONE, LEUR PRÉPARATION ET UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2014053568A1

  公开（公告）日：2014-04-10

  The invention relates to the novel products of formula (I): in which R1 represents H, Alk or cycloalkyl optionally substituted with one or more Hal; R2 represents H or Hal; and R3 represents H; Hal, OH; NO2; C2-C6 alkenyl; C2-C6 alkynyl; -Y-alkyl; R; OR; -CO2H; -CO2R; -NRxRy, -CONRxRy or -CO2NRxRy, all optionally substituted; where Y represents S, SO or SO2; NRxRy is such that either Rx represents H, alk or cycloalkyl and Ry represents H, alk, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, COR or SO2R, all optionally substituted; or Rx and Ry form, with N, an optionally substituted cyclic radical; R represents alk, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, all optionally substituted; with one or more H representing a deuterium atom; these products being in any of the isomer forms, and the salts, as medicaments, in particular as anticancer agents.